Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Partially Remote
Drugs
Locations
Clinical Specialty
681-700 of 998 trials

Acute Spinal Cord Injury: NG004 Treatment

We are testing a new antibody treatment for patients with acute spinal cord injuries to see if it is safe and well-tolerated. This study will help us understand how the treatment works in the body.

Cervical Spinal Cord InjurySafety phase (I)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Spinocerebellar Ataxia and Huntington’s Disease: VO659 Treatment

We are investigating the safety of a new treatment given through the spine for people with spinocerebellar ataxia types 1 and 3, and Huntington’s disease. This study aims to understand how the body processes the medication.

Spinocerebellar Ataxia Types 1, 3 and Huntington's Disease1-2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteNeurology

Ocular Melanoma: Roginolisib Treatment Study

We are studying the effectiveness of roginolisib for patients with advanced ocular or uveal melanoma compared to standard therapies. The trial will also assess safety and quality of life impacts.

Uveal MelanomaEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyOphthalmology

Burn Patients: Antibiotic Use Before Surgery

We are studying whether giving antibiotics before skin graft surgery helps reduce infections and complications in burn patients. This research may provide insights into improving recovery and hospital stays.

Burn Injury>2 yearsConfirmation phase (III)Standard MedicinesPartially RemoteInfectious DiseasesOrthopedics and Traumatology

Systemic Lupus Erythematosus: Cenerimod Study

We are examining the long-term safety and tolerability of cenerimod in adults with systemic lupus erythematosus. This study looks at how the medication works alongside existing treatments.

Systemic Lupus Erythematosus>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

PBP1510 for Advanced Pancreatic Cancer

We are studying a new treatment called PBP1510 in patients with advanced pancreatic cancer that has not responded to previous chemotherapy. The trial will evaluate its safety and effectiveness, both alone and with another drug, gemcitabine.

Advanced Pancreatic CancerSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Short-Term Insomnia: Neurexan® Treatment

We are exploring whether Neurexan® can improve sleep quality and daytime performance in people with short-term insomnia. This study compares its effects to a placebo to understand its potential benefits.

Short-Term Insomnia>2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteNeurologyPsychiatry

Kidney Transplant: Regulatory T Cell Therapy

We are studying the safety of using regulatory T cells in kidney transplant recipients to see if it helps the body accept the new kidney better. This may allow for less reliance on standard immunosuppressive medications.

Kidney TransplantationSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteInternal MedicineNephrology

Ileal Crohn’s Disease: AZD7798 Study

We are testing the safety and effectiveness of AZD7798 in adults with ileal Crohn’s disease who have an ileostomy. This study aims to see how well the treatment helps with healing and managing symptoms.

Crohn's Disease1-2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Heart Health: Apixaban vs. Warfarin Study

We are comparing two medications to see which is more effective in resolving blood clots in patients with left ventricular thrombus after a heart attack. We're also looking at safety and bleeding risks associated with each treatment.

Acute Myocardial InfarctionLeft Ventricular Thrombosis3-6 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Breast Cancer: Shorter Hormone Therapy Duration

We are studying whether limiting hormone therapy to 2 years is effective for women with hormone-sensitive breast cancer at very low risk of recurrence. This trial aims to assess the safety and quality of life during and after treatment.

Localized Luminal A Breast Cancer in Post-Menopausal Women>2 yearsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesPartially RemoteEndocrinologyOncology

Focal Onset Seizures: Extended-Release Levetiracetam Study

We are testing a new once-daily version of levetiracetam for people with drug-resistant focal onset seizures. The study aims to see if it reduces seizure frequency better than current treatments and a placebo.

Refractory Epilepsy3-6 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Duchenne Muscular Dystrophy: SGT-003 Gene Therapy

We are studying a new gene therapy to see if it is safe and effective for males with Duchenne Muscular Dystrophy. The trial will assess improvements in muscle function and other health measures after a single intravenous dose.

Duchenne Muscular Dystrophy>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteNeurology

Systemic Sclerosis: Efgartigimod PH20 SC Study

We are testing a new treatment for adults with systemic sclerosis to see if it improves skin symptoms and overall health compared to a placebo. The study will also look at safety and how well the treatment works.

Systemic Sclerosis1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteDermatologyRheumatology

APL-101 for Advanced Non-Small Cell Lung Cancer

We are studying a new treatment, APL-101, for patients with advanced solid tumors, including non-small cell lung cancer with specific genetic mutations. The trial aims to assess its safety and effectiveness, as well as find the best dose.

Non-Small Cell Lung CancerCentral Nervous System NeoplasmSolid Tumors>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Dexmedetomidine for Pain Management in Pediatric Surgery

We are studying whether adding intravenous dexmedetomidine to local anesthesia helps reduce pain after surgery in children. This trial will also look at how it affects recovery and any side effects.

Loco-regional Anesthesia in Pediatric Surgery6-12 monthsEfficacy phase (II)Standard MedicinesPartially RemoteInternal MedicineOtolaryngologyPediatrics

Focal Seizures: PRAX-628 Study

We are testing a new medication, PRAX-628, for adults with focal seizures to see if it can reduce seizure frequency compared to a placebo. The study also looks at the safety and tolerability of this treatment.

Focal EpilepsyEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurology

Hidradenitis Suppurativa: AVTX-009 Treatment Study

We are evaluating a new treatment, AVTX-009, for individuals with moderate to severe hidradenitis suppurativa. The goal is to see if it works better than a placebo and to check its safety.

Hidradenitis Suppurativa3-6 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyInternal Medicine

Inclisiran for Children with High Cholesterol

We are studying the safety and effectiveness of inclisiran in children aged 2 to under 12 years with homozygous familial hypercholesterolemia. The goal is to see if it can lower their cholesterol levels compared to a placebo.

Homozygous Familial Hypercholesterolemia>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPediatrics

Progressive Multiple Sclerosis: IMU-838 Study

We are testing a new medication, IMU-838, to see if it helps reduce brain atrophy in patients with progressive multiple sclerosis. This study compares its effects to a placebo to evaluate its safety and tolerability.

Progressive Multiple Sclerosis>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology